135 related articles for article (PubMed ID: 2242426)
1. The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Bierer BE; Nathan DG
Blood; 1990 Nov; 76(10):2052-9. PubMed ID: 2242426
[TBL] [Abstract][Full Text] [Related]
2. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Kicic A; Chua AC; Baker E
Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
[TBL] [Abstract][Full Text] [Related]
3. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
4. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
Stahel E; Mazier D; Guillouzo A; Miltgen F; Landau I; Mellouk S; Beaudoin RL; Langlois P; Gentilini M
Am J Trop Med Hyg; 1988 Sep; 39(3):236-40. PubMed ID: 3052118
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
6. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic.
Baker E; Wong A; Peter H; Jacobs A
Br J Haematol; 1992 Jul; 81(3):424-31. PubMed ID: 1340769
[TBL] [Abstract][Full Text] [Related]
7. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
8. Interference with oxidative processes inhibits proliferation of human peripheral blood lymphocytes and murine B-lymphocytes.
Hunt NH; Cook EP; Fragonas JC
Int J Immunopharmacol; 1991; 13(7):1019-26. PubMed ID: 1761347
[TBL] [Abstract][Full Text] [Related]
9. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron RJ; Wiegand J; Bharti N; McManis JS
J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
[TBL] [Abstract][Full Text] [Related]
10. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships among desazadesferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
[TBL] [Abstract][Full Text] [Related]
12. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation suppresses mononuclear cell activation, modifies lymphocyte migration patterns, and prolongs rat cardiac allograft survival in rats.
Whitley WD; Hancock WW; Kupiec-Weglinski JW; DeSousa M; Tilney NL
Transplantation; 1993 Nov; 56(5):1182-8. PubMed ID: 8249121
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelator desferrithiocin blocks allogeneic mononuclear cell activation and cytokine production in vivo and prolongs rat cardiac allograft survival.
Hancock WW; Whitley D; Kupiec-Weglinski JW; Tilney NL
Transplant Proc; 1992 Feb; 24(1):214-5. PubMed ID: 1539252
[No Abstract] [Full Text] [Related]
15. Effect of an iron-chelating agent on lymphocyte proliferation.
Bowern N; Ramshaw IA; Badenoch-Jones P; Doherty PC
Aust J Exp Biol Med Sci; 1984 Dec; 62 ( Pt 6)():743-54. PubMed ID: 6241825
[TBL] [Abstract][Full Text] [Related]
16. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2: induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity.
Yamada S; Ruscetti FW; Overton WR; Herberman RB; Birchenall-Sparks MC; Ortaldo JR
J Leukoc Biol; 1987 Jun; 41(6):505-17. PubMed ID: 3110337
[TBL] [Abstract][Full Text] [Related]
17. A comparative evaluation of iron clearance models.
Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
[TBL] [Abstract][Full Text] [Related]
18. A non-human primate model for the study of oral iron chelators.
Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
[TBL] [Abstract][Full Text] [Related]
19. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Longueville A; Crichton RR
Biochem Pharmacol; 1986 Nov; 35(21):3669-78. PubMed ID: 3778498
[TBL] [Abstract][Full Text] [Related]
20. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
Jin Y; Baquet A; Florence A; Crichton RR; Schneider YJ
Biochem Pharmacol; 1989 Oct; 38(19):3233-40. PubMed ID: 2818622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
